AstraZeneca: Trial shows Vaxzevria’s worth as Covid-19 booster jab

Published by

The ongoing D7220C00001 safety and immunogenicity trial of Covid-19 vaccine Vaxzevria (ChAdOx1-S) as a third dose booster is yielding positive results, British pharmaceutical firm AstraZeneca announced on Thursday. A preliminary analysis showed that a Vaxzevria third dose booster increased the immune response to the Beta, Delta, Alpha and Gamma SARS-CoV-2 variants. An additional analysis of samples from the trial showed increased antibody response to the Omicron variant as well. The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine. Further,…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *